direct oral anticoagulant (DAO)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
dabigatran
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%
ximelagatran
ESTEEM, 2003   ximelagatranplaceboExploratory -

atrial fibrillation

apixaban
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-30%-11%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
dabigatran
phase 2 dabigatran    NCTdabigatranwarfarin standard doseExploratory -
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting-20%-9%
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting -7%-12%
edoxaban
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting -20%-8%
idraparinux
AMADEUS, 2008      NCTidraparinuxwarfarin standard doseRisk of bias negative 167%12%
rivaroxaban
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting 4%-8%
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting-29%-1%
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting -25%-6%

cardiovascular prevention

rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCTrivaroxabanaspirinsecondary prevention -
COMPASS (rivaroxaban + aspirin), 2017      NCTrivaroxaban + aspirinaspirinsecondary preventionLow risk of bias - 8100%

heart failure

rivaroxaban
COMMANDER HF, 2018      NCTrivaroxabanplacebonegative-2%

thrombosis prevention

apixaban
ADOPT, 2011      NCTapixabanenoxaparinmedical patientsLow risk of bias suggesting153%
ADVANCE 3, 2010    NCTapixabanenoxaparinhip surgeryLow risk of bias suggesting22%199%
ADVANCE 2, 2010      NCTapixabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting-35%+Infini%
APROPOS 2.5mg, 2007    NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias negative+Infini%
ADVANCE-1, 2008      NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting-50%0%
betrixaban
APEX, 2016    NCTbetrixabanenoxaparinmedical patientsLow risk of bias suggesting19%
dabigatran
RE-NOVATE (150mg), 2007      NCTdabigatran 150mgenoxaparinhip surgeryLow risk of bias negative -17%
RE-NOVATE (220mg), 2007      NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative29%+Infini%
RE-NOVATE 2    NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-MODEL (150mg), 2007     dabigatran 150mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative-1%-2%
RE-MODEL (220mg), 2007   dabigatran 220mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative14%1%
RE-MOBILIZE (150mg), 2008     dabigatran 150mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%+Infini%
RE-MOBILIZE (220mg), 2008     dabigatran 220mgenoxaparin (US regimen)knee surgeryLow risk of bias negative -58%
edoxaban
STARS J-V    NCTedoxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
rivaroxaban
MARINER, 2018        NCTrivaroxabanplacebomedical patientsLow risk of bias suggesting 88%-20%
RECORD 1, 2008      NCTrivaroxabanenoxaparinhip surgeryLow risk of bias suggesting202%-2%
RECORD 3, 2008    NCTrivaroxabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting19%-100%
ODIXa-HIP 10mg, 2006   rivaroxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
RECORD 2, 2008    NCTrivaroxaban (long duration)enoxaparin (short duration)hip surgeryLow risk of bias suggesting0%-66%
ODIXa-KNEE, 2005   rivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias negative-100%
RECORD 4, 2009    NCTrivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting147%-34%

venous thrombosis

apixaban
AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting-51%
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting-75%
Botticelli DVT, 2008      NCTapixaban (without LMWH)LMWH/VKAExploratory -
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-69%-21%
dabigatran
RE-MEDY, 2011      NCTdabigatranwarfarinLow risk of bias suggesting-48%-11%
RE-SONATE, 2011    NCTdabigatrandiscontinuationLow risk of bias suggesting+Infini%-100%
RE-COVER, 2009      NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting-17%-1%
RE-COVER II, 2011    NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting-31%
edoxaban
Hokusai-VTE Cancer, 2017      NCTedoxabandalteparinpatients with cancerRisk of bias negative 77%12%
Edoxaban Hokusai VTE, 2013      NCTheparin/edoxabanheparin/VKA heparin - DOAC Low risk of bias suggesting-15%
idraparinux
Van Gogh (subgroup), 2011     idraparinuxstandard treatmentpatients with cancerExploratory negative
rivaroxaban
SELECT D, 2018     rivaroxabandalteparinpatients with cancerRisk of bias suggesting 83%
EINSTEIN-extension, 2009    NCTrivaroxabandiscontinuationLow risk of bias suggesting +Infini%-51%
EINSTEIN (subgroup), 2014     rivaroxabanenoxaparinpatients with cancersuggesting-58%-7%
Einstein-DVT Dose-Ranging Study, 2008     rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010    NCTrivaroxaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-30%-23%
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -
rosuvastatin
VanGogh extension, 2007      NCTidraparinuxdiscontinuationsuggesting +Infini%
ximelagatran
THRIVE III, 2003       ximelagatrandiscontinuationLow risk of bias suggesting20%-14%
Schulman (subgroup), 2003     ximelagatranplacebopatients with cancer -
THRIVE I, 2003   ximelagatran (without LMWH)LMWH/VKA -